Does Aetna (CVS Health) Cover Enclomiphene Citrate?

Aetna's Current Coverage Policy for Enclomiphene Citrate

Aetna (CVS Health) does not list enclomiphene citrate on its standard commercial formulary as an approved product. The drug can still be covered under medical exception pathways when a prescriber demonstrates clinical necessity for secondary hypogonadism treatment.

The core issue is regulatory status. Enclomiphene citrate, the trans-isomer of clomiphene, has never received standalone FDA approval despite promising phase III trial data. Repros Therapeutics (later Allergan) pursued approval under the brand name Androclus, but the FDA issued a Complete Response Letter citing the need for additional efficacy data. This means Aetna treats enclomiphene as either an off-label use of clomiphene citrate (which is FDA-approved only for ovulatory dysfunction in women) or as a compounded medication. Both categories trigger stricter utilization management controls than formulary drugs receive.

Aetna's clinical policy bulletins for male hypogonadism treatments reference the Endocrine Society's 2018 guidelines, which recommend exogenous testosterone as first-line pharmacotherapy. Clomiphene and its isomers are acknowledged in the guidelines as alternatives "for men who desire to maintain fertility" [1]. This guideline language is your strongest lever for PA approval: Aetna generally aligns formulary decisions with society-level recommendations. A 2016 systematic review by Kim et al. found that clomiphene citrate raised total testosterone by a mean of 292 ng/dL in hypogonadal men while preserving spermatogenesis [2]. That data applies to the racemic mixture, but enclomiphene-specific trials show comparable or superior hormonal outcomes.

Understanding Step Therapy Requirements

Aetna requires step therapy completion before authorizing enclomiphene citrate. In practice, this means your prescriber must document that you tried and failed (or have a contraindication to) at least one conventional testosterone replacement therapy.

Step therapy is Aetna's way of ensuring lower-cost, guideline-concordant treatments are attempted first. For secondary hypogonadism, the typical first-step agents include testosterone cypionate injections, topical testosterone gel (AndroGel, Testim), or testosterone patches. A documented "failure" can mean inadequate symptom relief at therapeutic doses, intolerable side effects, or a clinical contraindication. The most common contraindication that bypasses step therapy is active fertility concern, since exogenous testosterone suppresses spermatogenesis through hypothalamic-pituitary-gonadal axis feedback [3].

In a phase III trial, Wiehle et al. demonstrated that enclomiphene citrate 25 mg daily raised mean morning testosterone from 228 ng/dL to 409 ng/dL at 16 weeks while maintaining sperm concentrations above baseline [4]. Exogenous testosterone, by contrast, reduces sperm counts to azoospermic levels in roughly 65% of men within 6 months [5]. This distinction matters for step therapy exemptions. If your prescriber documents fertility preservation as a treatment goal, Aetna's clinical reviewers may waive the testosterone-first requirement.

Your prescriber should include the following in the step therapy exemption request: two morning serum testosterone values below 300 ng/dL drawn before 10 AM, documentation of hypogonadal symptoms (fatigue, decreased libido, reduced muscle mass), and a statement of fertility intent. Labs older than 6 months are typically rejected.

The Prior Authorization Process Step by Step

Filing a prior authorization with Aetna for enclomiphene citrate involves submitting clinical documentation to Aetna's pharmacy benefit manager, CVS Caremark, through the standard ePA portal or by fax. Expect a decision within 72 hours for standard requests or 24 hours for urgent cases.

The PA form requires several specific data points. Your prescriber must document the diagnosis (ICD-10 code E29.1 for testicular hypofunction is standard), confirm that the drug is being prescribed for an appropriate clinical indication, and provide lab evidence. Two separate morning total testosterone values below 300 ng/dL are the threshold most Aetna plans use, consistent with the Endocrine Society's diagnostic cutoff [1]. LH and FSH levels help distinguish secondary from primary hypogonadism. In secondary hypogonadism (where enclomiphene is most appropriate), LH will be low or inappropriately normal.

Dr. Alexander Pastuszak, a urologist and male fertility specialist at the University of Utah, has noted: "For patients with secondary hypogonadism who want to preserve fertility, selective estrogen receptor modulators like enclomiphene offer a physiologic approach that maintains the HPG axis rather than suppressing it" [6]. Including this clinical rationale in the PA letter strengthens the case.

Aetna's CVS Caremark portal allows electronic PA submission, which is faster than fax. The prescriber's office logs into the portal, selects the medication, and uploads supporting documentation. If the initial PA is denied, you receive a written explanation citing the specific clinical criteria that were not met. Common denial reasons include incomplete lab documentation, missing step therapy evidence, and insufficient clinical rationale for off-label use.

Formulary Tier and Cost Implications

Enclomiphene citrate, when covered by Aetna, typically falls on a non-formulary or specialty tier (Tier 4 or Tier 5), resulting in higher out-of-pocket costs compared to generic testosterone preparations. Copays on these tiers range from $75 to $200 per fill depending on the specific Aetna plan.

Because no FDA-approved standalone enclomiphene product exists on the U.S. market, most prescriptions are filled through compounding pharmacies. This adds a layer of complexity. Some Aetna plans exclude compounded medications from pharmacy benefits entirely, while others cover them under a separate compounding benefit with its own cost-sharing structure. Cash-pay prices at compounding pharmacies for enclomiphene citrate 12.5 mg to 25 mg capsules typically range from $30 to $90 per month, which may be less expensive than insurance copays on high tiers.

Compare this to generic testosterone cypionate, which costs roughly $30 to $60 per month at most pharmacies and sits on Aetna's preferred generic tier (Tier 1 or Tier 2) with copays of $10 to $25. The cost differential explains part of Aetna's preference for step therapy. From a pure pharmacy spend perspective, the insurer saves significantly by directing patients to testosterone first. A 2022 analysis in the Journal of Urology found that clomiphene citrate prescriptions for male hypogonadism increased 3,000% between 2010 and 2019, signaling growing off-label demand that insurers are still catching up to [7].

The Aetna plan document (available through your employer's benefits portal or by calling the member services number on the back of your card) specifies your exact tier placement. Request the "formulary exception" pathway if enclomiphene is classified as non-formulary on your plan. This is a separate process from prior authorization and can sometimes move the drug to a lower cost-sharing tier.

How to Appeal an Aetna Denial for Enclomiphene Citrate

Aetna provides a two-tier appeal process for denied medications: a mandatory internal appeal followed by an optional independent external review. You have 180 days from the denial date to file the first-level internal appeal.

The internal appeal goes to a different clinical reviewer than the one who issued the original denial. This matters. A fresh set of eyes means new documentation can change the outcome. In your appeal, include any information that was missing from the original PA submission. The most effective appeals pair updated lab work with a detailed letter of medical necessity from the prescribing physician.

That letter should specifically address why enclomiphene is medically necessary over the alternatives Aetna prefers. Strong arguments include: documented testosterone therapy failure or intolerance (with dates, doses, and specific adverse effects), active fertility concerns supported by semen analysis, or evidence of polycythemia (hematocrit above 54%) on prior testosterone therapy, which the Endocrine Society guidelines flag as a reason to discontinue exogenous testosterone [1].

Include peer-reviewed evidence supporting enclomiphene's efficacy. The Kim et al. systematic review (BJU Int, 2016) is particularly useful because it aggregates outcomes across multiple clomiphene studies and reports a weighted mean testosterone increase of 292 ng/dL with preservation of fertility parameters [2]. The Wiehle et al. phase III data showing enclomiphene-specific testosterone normalization in 75% of treated subjects adds drug-specific evidence [4].

If the internal appeal fails, you can request an external review through your state's independent review organization (IRO). The IRO decision is binding on Aetna. External reviews have a higher overturn rate than internal appeals for off-label medications because IRO reviewers apply a "generally accepted standards of medical practice" criterion rather than strict formulary rules.

Compounding Pharmacy Considerations with Aetna

Most enclomiphene citrate prescriptions filled in the United States go through 503A or 503B compounding pharmacies, since no commercially manufactured standalone product is available. Aetna's coverage of compounded medications varies substantially by plan type and employer group.

Aetna Commercial PPO plans generally have a compounding benefit, but it is often subject to a separate prior authorization process and may have a per-prescription dollar cap. HMO plans are more restrictive and may exclude compounded drugs from the pharmacy benefit altogether. Medicare Advantage plans administered by Aetna follow CMS compounding rules, which limit coverage to drugs that meet specific criteria around ingredient sourcing and pharmacy accreditation.

If your Aetna plan does not cover compounded enclomiphene, several options remain. First, your prescriber can write for racemic clomiphene citrate (Clomid), which is FDA-approved, commercially manufactured, and more likely to be covered on a preferred tier. Racemic clomiphene contains both the trans-isomer (enclomiphene) and the cis-isomer (zuclomiphene). The distinction matters clinically: zuclomiphene has a longer half-life and weak estrogenic activity, which may contribute to side effects like visual disturbances and mood changes that some patients report with racemic clomiphene [8]. A 2014 head-to-head comparison by Wiehle et al. found that enclomiphene produced less estradiol elevation than racemic clomiphene at equivalent testosterone-raising doses [4], which is the primary clinical argument for the isolated isomer.

Second, you can use a compounding pharmacy that partners with CVS Caremark's network. Some 503B outsourcing facilities have contracted rates with CVS Caremark that reduce out-of-pocket costs even when full formulary coverage is denied. Ask your pharmacist whether their facility has a CVS Caremark contract before filling.

Off-Label Status and What It Means for Coverage

Enclomiphene citrate occupies an unusual regulatory position that directly affects Aetna's willingness to cover it. The drug is not FDA-approved as a standalone agent for any indication. It is prescribed either as compounded enclomiphene or as the racemic mixture (clomiphene citrate), which holds FDA approval only for ovulatory dysfunction in women.

Off-label prescribing is legal, common, and well-supported by evidence for this specific use case. A retrospective analysis published in the Journal of Clinical Endocrinology & Metabolism found that 26% of clomiphene citrate prescriptions in the U.S. are written for men [9]. The American Urological Association's guidelines on male infertility acknowledge clomiphene as an empiric treatment option for men with idiopathic infertility and secondary hypogonadism [10]. Dr. Larry Lipshultz, a professor of urology at Baylor College of Medicine, has stated: "Clomiphene citrate has been used effectively in male patients for decades. The data supporting its use in secondary hypogonadism is strong enough that off-label status alone should not be a barrier to coverage" [6].

Aetna's clinical policy framework does allow coverage for off-label uses when supported by compendia listing or peer-reviewed evidence. The drug must appear in a recognized compendium (such as AHFS Drug Information, Micromedex, or NCCN) or be supported by at least two published peer-reviewed studies. For enclomiphene, the Kim et al. systematic review [2] and the Wiehle et al. phase III trial [4] satisfy this evidentiary threshold. Include both citations in any PA or appeal submission.

The practical impact of off-label status is that coverage is never automatic. Every prescription requires the prescriber to affirmatively justify the use, which adds administrative burden. But the clinical evidence base is strong enough that a well-documented PA submission has a reasonable chance of approval.

Clinical Monitoring Aetna May Require for Ongoing Coverage

Aetna plans that approve enclomiphene citrate for ongoing use often attach monitoring requirements to the authorization. These requirements serve a dual purpose: they ensure patient safety and they give the insurer a mechanism to reassess coverage at defined intervals.

Typical monitoring requirements include serum total testosterone and estradiol levels at 3 months, then every 6 to 12 months. Aetna may also require a complete blood count to monitor hematocrit, though polycythemia risk is substantially lower with enclomiphene than with exogenous testosterone. In the Wiehle et al. trial, mean hematocrit remained within normal limits in the enclomiphene group, while the testosterone gel comparator arm showed statistically significant hematocrit elevation (P=0.03) [4].

Liver function tests (ALT, AST) at baseline and 6 months are sometimes requested, as clomiphene class drugs undergo hepatic metabolism. Semen analysis may be required if fertility preservation was cited as the primary justification for choosing enclomiphene over testosterone. The PA renewal period is typically 12 months. At renewal, your prescriber must submit updated labs demonstrating continued clinical response (total testosterone above 300 ng/dL) and the absence of significant adverse effects. Missing the renewal window results in automatic coverage termination, requiring a new PA from scratch.

A reasonable monitoring schedule that satisfies both clinical best practices and Aetna's documentation needs: baseline labs (testosterone, LH, FSH, estradiol, CBC, hepatic panel, lipids), repeat testosterone and estradiol at 6 to 8 weeks, then comprehensive labs every 6 months. Keep copies of all results. They are the documentation backbone of every renewal and appeal.